ArticleFrontiers in oncology2021

Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.

Dan Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.